TEK and ovarian cancer: Firstly, in a Phase III trial, peptide-Fc fusion protein Trebananib, which targets Ang2, as well as additional Tie2 ligand, Ang1, was found to enhance PFS in ovarian cancer patients (Table 1) [23].